Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 9/2016

11.03.2016 | Original Article

18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease

verfasst von: Verena Ruhlmann, Thorsten Dirk Poeppel, Alexander Sascha Brandt, Johannes Grüneisen, Marcus Ruhlmann, Jens Matthias Theysohn, Michael Forsting, Andreas Bockisch, Lale Umutlu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate integrated 18F-FDG PET/MRI as a one-stop diagnostic procedure in the assessment of (active) idiopathic retroperitoneal fibrosis (RPF)

Methods

A total of 22 examinations comprising a PET/CT scan followed by a PET/MRI scan in 17 patients (13 men, 4 women, age 58 ± 11 years) with histopathologically confirmed RPF at diagnosis or during follow-up under steroid therapy were analysed in correlation with laboratory inflammation markers (ESR, CRP). The patient cohort was subdivided into two groups: 6 examinations in untreated and 16 in treated patients. Tissue formations in typically periaortic localization suggestive of RPF were visually and quantitatively evaluated. The PET analysis included the assessment of SUVmax and a qualitative score for FDG uptake in RPF tissue in relation to the uptake in the liver. MRI analysis included evaluation of the T2-weighted image signal intensity, contrast enhancement and diffusion restriction (ADC values). Mean values were compared using the Mann-Whitney U test. ADC, SUVmax and ESR values were correlated using Pearson’s correlation.

Results

MRI analysis revealed restricted diffusion in 100 % and 56 %, hyperintense T2 signal in 100 % and 31 %, and contrast enhancement in the periaortic tissue formation suggestive of RPF in 100 % and 62.5 % in the untreated and treated patients, respectively. In the qualitative and quantitative PET analysis, statistically significant differences were found for mean FDG uptake scores (2.5 ± 0.8 in untreated patients and 1.1 ± 0.9 in treated patients) and mean SUVmax (7.8 ± 3.5 and 4.1 ± 2.2, respectively). A strong correlation was found between the ADC values and SUVmax (Pearson r   −0.65, P = 0.0019), and between ESR and CRP values and SUVmax (both r = 0.45, P = 0.061).

Conclusion

Integrated 18F-FDG PET/MRI shows high diagnostic potential as a one-stop diagnostic procedure for the assessment of (active) RPF providing multiparametric supportive information.
Literatur
1.
Zurück zum Zitat Dineen J, Asch T, Pearce JM. Retroperitoneal fibrosis. An anatomic and radiologic review with a report of four new cases and an explanation of pathogenesis. Radiology. 1960;75:380–90.CrossRefPubMed Dineen J, Asch T, Pearce JM. Retroperitoneal fibrosis. An anatomic and radiologic review with a report of four new cases and an explanation of pathogenesis. Radiology. 1960;75:380–90.CrossRefPubMed
2.
Zurück zum Zitat Caiafa RO, Vinuesa AS, Izquierdo RS, Brufau BP, Ayuso Colella JR, Molina CN. Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics. 2013;33:535–52.CrossRefPubMed Caiafa RO, Vinuesa AS, Izquierdo RS, Brufau BP, Ayuso Colella JR, Molina CN. Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics. 2013;33:535–52.CrossRefPubMed
3.
4.
Zurück zum Zitat Geoghegan T, Byrne AT, Benfayed W, McAuley G, Torreggiani WC. Imaging and intervention of retroperitoneal fibrosis. Australas Radiol. 2007;51:26–34.CrossRefPubMed Geoghegan T, Byrne AT, Benfayed W, McAuley G, Torreggiani WC. Imaging and intervention of retroperitoneal fibrosis. Australas Radiol. 2007;51:26–34.CrossRefPubMed
5.
Zurück zum Zitat Heckmann M, Uder M, Kuefner MA, Heinrich MC. Ormond’s disease or secondary retroperitoneal fibrosis? An overview of retroperitoneal fibrosis. Rofo. 2009;181:317–23.CrossRefPubMed Heckmann M, Uder M, Kuefner MA, Heinrich MC. Ormond’s disease or secondary retroperitoneal fibrosis? An overview of retroperitoneal fibrosis. Rofo. 2009;181:317–23.CrossRefPubMed
6.
Zurück zum Zitat Brandt AS, Soares SB, Fehr A, Kukuk S, Mathers MJ, Störkel S, et al. “Retroperitoneal fibrosis” (RPF) urologic cooperation and research project. Urologe A. 2007;46:1302–4.CrossRefPubMed Brandt AS, Soares SB, Fehr A, Kukuk S, Mathers MJ, Störkel S, et al. “Retroperitoneal fibrosis” (RPF) urologic cooperation and research project. Urologe A. 2007;46:1302–4.CrossRefPubMed
7.
Zurück zum Zitat Burn PR, Singh S, Barbar S, Boustead G, King CM. Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis. Can Assoc Radiol J. 2002;53:168–70.PubMed Burn PR, Singh S, Barbar S, Boustead G, King CM. Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis. Can Assoc Radiol J. 2002;53:168–70.PubMed
8.
Zurück zum Zitat Kamper L, Brandt AS, Scharwächter C, Kukuk S, Roth S, Haage P, et al. MR evaluation of retroperitoneal fibrosis. Rofo. 2011;183:721–6.CrossRefPubMed Kamper L, Brandt AS, Scharwächter C, Kukuk S, Roth S, Haage P, et al. MR evaluation of retroperitoneal fibrosis. Rofo. 2011;183:721–6.CrossRefPubMed
9.
Zurück zum Zitat Brandt AS, Kamper L, Kukuk S, Piroth W, Haage P, Roth S. An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res. 2013;5:49–56.PubMedPubMedCentral Brandt AS, Kamper L, Kukuk S, Piroth W, Haage P, Roth S. An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res. 2013;5:49–56.PubMedPubMedCentral
10.
Zurück zum Zitat Kamper L, Brandt AS, Ekamp H, Abanador-Kamper N, Piroth W, Roth S, et al. Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis. Diagn Interv Radiol. 2014;20:459–63.CrossRefPubMedPubMedCentral Kamper L, Brandt AS, Ekamp H, Abanador-Kamper N, Piroth W, Roth S, et al. Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis. Diagn Interv Radiol. 2014;20:459–63.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Jansen I, Hendriksz TR, Han SH, Huiskes AW, van Bommel EF. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med. 2010;21:216–21.CrossRefPubMed Jansen I, Hendriksz TR, Han SH, Huiskes AW, van Bommel EF. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med. 2010;21:216–21.CrossRefPubMed
12.
Zurück zum Zitat Yilmaz S, Tan YZ, Ozhan M, Halac M, Asa S, et al. FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol. 2012;31:338–9.PubMed Yilmaz S, Tan YZ, Ozhan M, Halac M, Asa S, et al. FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. Rev Esp Med Nucl Imagen Mol. 2012;31:338–9.PubMed
13.
Zurück zum Zitat Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging. 2012;39:1635–42.CrossRefPubMed Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging. 2012;39:1635–42.CrossRefPubMed
14.
Zurück zum Zitat Bertagna F, Treglia G, Leccisotti L, Bosio G, Motta F, Giordano A, et al. [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol. 2012;30:415–21.CrossRefPubMed Bertagna F, Treglia G, Leccisotti L, Bosio G, Motta F, Giordano A, et al. [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol. 2012;30:415–21.CrossRefPubMed
15.
Zurück zum Zitat Vaglio A, Greco P, Versari A, Filice A, Cobelli R, Manenti L, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol. 2005;23:231–4.PubMed Vaglio A, Greco P, Versari A, Filice A, Cobelli R, Manenti L, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol. 2005;23:231–4.PubMed
16.
Zurück zum Zitat Washino S, Hirai M, Matsuzaki A, Kobayashi Y. (18)F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis. Ann Nucl Med. 2010;24:225–9.CrossRefPubMed Washino S, Hirai M, Matsuzaki A, Kobayashi Y. (18)F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis. Ann Nucl Med. 2010;24:225–9.CrossRefPubMed
17.
Zurück zum Zitat Young PM, Peterson JJ, Calamia KT. Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18FDG PET: report of three cases. Ann Nucl Med. 2008;22:87–92.CrossRefPubMed Young PM, Peterson JJ, Calamia KT. Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18FDG PET: report of three cases. Ann Nucl Med. 2008;22:87–92.CrossRefPubMed
18.
Zurück zum Zitat Martinez-Möller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520–6.CrossRefPubMed Martinez-Möller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520–6.CrossRefPubMed
19.
Zurück zum Zitat Bini J, Robson PM, Calcagno C, Eldib M, Fayad ZA. Quantitative carotid PET/MR imaging: clinical evaluation of MR-attenuation correction versus CT-attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT. Am J Nucl Med Mol Imaging. 2015;5:293–304.PubMedPubMedCentral Bini J, Robson PM, Calcagno C, Eldib M, Fayad ZA. Quantitative carotid PET/MR imaging: clinical evaluation of MR-attenuation correction versus CT-attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT. Am J Nucl Med Mol Imaging. 2015;5:293–304.PubMedPubMedCentral
20.
Zurück zum Zitat Schaarschmidt BM, Heusch P, Buchbender C, Ruhlmann M, Bergmann C, Ruhlmann V, et al. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging. 2016;43:92–102.CrossRefPubMed Schaarschmidt BM, Heusch P, Buchbender C, Ruhlmann M, Bergmann C, Ruhlmann V, et al. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging. 2016;43:92–102.CrossRefPubMed
22.
Zurück zum Zitat Guignard R, Simukoniene M, Garibotto V, Ratib O. 18F-FDG PET/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med. 2012;37:453–9.CrossRefPubMed Guignard R, Simukoniene M, Garibotto V, Ratib O. 18F-FDG PET/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med. 2012;37:453–9.CrossRefPubMed
23.
Zurück zum Zitat Vivas I, Nicolás AI, Velázquez P, Elduayen B, Fernández-Villa T, Martínez-Cuesta A. Retroperitoneal fibrosis: typical and atypical manifestations. Br J Radiol. 2000;73:214–22.CrossRefPubMed Vivas I, Nicolás AI, Velázquez P, Elduayen B, Fernández-Villa T, Martínez-Cuesta A. Retroperitoneal fibrosis: typical and atypical manifestations. Br J Radiol. 2000;73:214–22.CrossRefPubMed
24.
Zurück zum Zitat Varoquaux A, Rager O, Poncet A, Delattre BM, Ratib O, Becker CD, et al. Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:462–75.CrossRefPubMed Varoquaux A, Rager O, Poncet A, Delattre BM, Ratib O, Becker CD, et al. Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:462–75.CrossRefPubMed
25.
Zurück zum Zitat Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and follow up of idiopathic retroperitoneal fibrosis. Arthritis Rheum. 2005;53:122–5.CrossRefPubMed Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and follow up of idiopathic retroperitoneal fibrosis. Arthritis Rheum. 2005;53:122–5.CrossRefPubMed
26.
Zurück zum Zitat Piccoli GB, Consiglio V, Arena V, Pelosi E, Anastasios D, Ragni F, et al. Positron emission tomography as a tool for the “tailored” management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transplant. 2010;25:2603–10.CrossRefPubMed Piccoli GB, Consiglio V, Arena V, Pelosi E, Anastasios D, Ragni F, et al. Positron emission tomography as a tool for the “tailored” management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transplant. 2010;25:2603–10.CrossRefPubMed
27.
Zurück zum Zitat Pietrzyk U, Herzog H. Does PET/MR in human brain imaging provide optimal co-registration? A critical reflection. MAGMA. 2013;26:137–47.CrossRefPubMed Pietrzyk U, Herzog H. Does PET/MR in human brain imaging provide optimal co-registration? A critical reflection. MAGMA. 2013;26:137–47.CrossRefPubMed
28.
Zurück zum Zitat Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.PubMed Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.PubMed
29.
Zurück zum Zitat Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. 2009;61:674–9.CrossRefPubMed Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. 2009;61:674–9.CrossRefPubMed
30.
Zurück zum Zitat Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, et al. Standardized uptake values for [18F]FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol. 2013;82:870–6.CrossRefPubMed Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, et al. Standardized uptake values for [18F]FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol. 2013;82:870–6.CrossRefPubMed
31.
Zurück zum Zitat Grueneisen J, Beiderwellen K, Heusch P, Buderath P, Aktas B, Gratz M, et al. Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer. PLoS One. 2014;9,e96751.CrossRefPubMedPubMedCentral Grueneisen J, Beiderwellen K, Heusch P, Buderath P, Aktas B, Gratz M, et al. Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer. PLoS One. 2014;9,e96751.CrossRefPubMedPubMedCentral
Metadaten
Titel
18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease
verfasst von
Verena Ruhlmann
Thorsten Dirk Poeppel
Alexander Sascha Brandt
Johannes Grüneisen
Marcus Ruhlmann
Jens Matthias Theysohn
Michael Forsting
Andreas Bockisch
Lale Umutlu
Publikationsdatum
11.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3351-3

Weitere Artikel der Ausgabe 9/2016

European Journal of Nuclear Medicine and Molecular Imaging 9/2016 Zur Ausgabe